News
Dapagliflozin approved for reducing HF hospitalization in diabetes
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
News
FDA declines dapagliflozin indication as adjunct for type 1 diabetes
AstraZeneca says it has received a complete response letter, but gives no reason for the agency’s decision.
Video
AACE 2019: Top takeaways from Yehuda Handelsman and Paul Jellinger
LOS ANGELES – Yehuda Handelsman, MD, and Paul S. Jellinger, MD, summarized some of the key takeaways from this year’...
